Advertisement.
Advertisement.
Advertisement
Advertisement.
LXRX Lexicon Pharmaceuticals Inc
12,278
| Market Cap | $863.97M |
| Volume | 3.14M |
| 52-Wk High | $3.73 |
| 52-Wk Low | $0.92 |
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire•4 months ago
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon's president and chief financial officer, Tom Garner...
Share to Feed
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...
Globe Newswire•4 months ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Get Free Report) was the recipient of a significant drop in short interest in February. As of February 29th, there was short interest totalling...
Zolmax•4 months ago
KWB Wealth bought a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and...
Ticker Report•4 months ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Get Free Report) fell 6.8% on Tuesday . The stock traded as low as $2.51 and last traded at $2.62. 3,249,144 shares were traded during mid-day...
Zolmax•4 months ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Get Free Report)s stock price gapped up before the market opened on Monday . The stock had previously closed at $2.17, but opened at $2.32...
Zolmax•5 months ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors bought 7,172 call options on the company. This...
Zolmax•5 months ago
THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...
Globe Newswire•5 months ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX Get Free Report) shares were down 6.8% during trading on Tuesday . The stock traded as low as $2.51 and last traded at $2.62. Approximately...
Ticker Report•5 months ago
Commercial launch of INPEFA (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase...
Globe Newswire•5 months ago